Pahr Therapeutics Secures $14M to Advance New Treatments for Pulmonary Arterial Hypertension

A Big Leap Forward in PAH Care Pahr Therapeutics Inc. has raised $14 million in seed funding to accelerate its mission of developing cutting-edge therapies for pulmonary arterial hypertension (PAH) a rare, progressive disease that affects the lungs and heart. The funding round was led by AN Venture Partners, RA Capital Management, and University of Tokyo Edge Capital Partners (UTEC). As part of this exciting milestone, Andrew Levin (MD/PhD, RA Capital), Atsushi Usami (PhD, UTEC), and Ken Horne (Managing Partner, AN Venture Partners) have joined Pahr’s board of directors, bringing deep expertise and strategic support to help drive the company’s next phase of growth. The Science Behind Pahr Pahr Therapeutics was incubated at Raven, a venture creation engine backed by RA Capital, and is led by Neil Buckley, a venture partner at Raven. The company was co-founded by three distinguished scientists from Japan’s National Cerebral and Cardiovascular Center (NCVC) in Osaka:

• Dr. Makoto Okazawa
• Dr. Ryotaro Asano
• Dr. Yoshikazu Nakaoka

Dr. Nakaoka, who heads the vascular physiology department at NCVC, has spent decades at the forefront of PAH research. His groundbreaking work in understanding the molecular mechanisms of PAH laid the foundation for Pahr’s therapeutic approach. He was also a finalist in Science2Startup Japan 2024, where his work caught the attention of RA Capital’s Andrew Levin ultimately leading to the creation of Pahr Therapeutics. Become a valued research partner with us - https://www.towardshealthcare.com/schedule-meeting What This Means for the Future of PAH Treatment This funding isn’t just about capital it’s about accelerating hope. With the combined support of global investors and some of the brightest minds in cardiovascular science, Pahr aims to push its innovative therapies toward clinical trials as early as next year. The goal is to deliver effective, accessible treatments for PAH patients worldwide. Beyond patient impact, this initiative opens doors for hospitals, researchers, and healthcare professionals to explore new therapeutic approaches, expand their clinical expertise, and contribute to life-changing advancements in care. Voices from the Frontline Dr. Nakaoka shared: "I’m honored to work alongside RA Capital, UTEC, and AN Venture Partners. Their belief in our mission and support of our science empower us to move quickly into clinical development. We’re excited about what’s ahead." Request a customized case study tailored to your business needs and gain deeper insights into healthcare market strategies: [email protected]